Sigma-Tau Finanziaria
Baxter buys cancer portfolio for $900 million
May 13, 2015Research and Development, Sales and Marketing Cancer, Oncaspar, Sigma-Tau Finanziaria, baxter, oncology
Baxter is buying leukaemia treatment Oncaspar from Italian firm Sigma-Tau Finanziaria for $900 million as the US firm looks to …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
